CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Aveo Pharmaceuticals, Inc.

AVEO
N/A

Next catalyst

Phase 3August 2027

Ficlatuzumab

Metastatic Head-and-neck Squamous-cell Carcinoma

Get an email about AVEO's next catalysts

Track Aveo Pharmaceuticals (AVEO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 4 past

Phase 3Next

Ficlatuzumab Phase 3 Est. Readout (FIERCE-HN)

August 2027~Ficlatuzumab410

Primary completion for Ficlatuzumab trial (NCT06064877) in Metastatic Head-and-neck Squamous-cell Carcinoma

Source

Market Overview

Stock performance and key metrics

NASDAQHealthcareπŸ‡ΊπŸ‡ΈNorth America
Drug Pipeline

Samalizumab (BAML-16-001-S1)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Ficlatuzumab

Phase 3

Metastatic Head-and-neck Squamous-cell Carcinoma

Tivozanib

Phase 3

Renal Cell Carcinoma

Tivozanib hydrochloride

Phase 3

Carcinoma, Renal Cell

Daunorubicin or Idarubicin (BAML-16-001-S25/HO181)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

tivozanib (AV-951)

Phase 3

Advanced Renal Cell Carcinoma

Decitabine (BAML-16-001-S5)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

AZD5991 (BAML-16-001-S18)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Bleximenib (BAML-16-001-S25/HO181)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Revumenib (BAML-16-001-S26/HO177)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Daunorubicin (BAML-16-001-S1)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Entospletinib (BAML-16-001-S4)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Gilteritinib (BAML-16-001-S8 Group 1)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

AG-120 (BAML-16-001-S16)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Decitabine (BAML-16-001-S8 Group 2)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

ZE46-0134 (BAML-16-001-S21 Group 1)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Pevonedistat (BAML-16-001-S9)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

TP-0903 (BAML-16-001-S14)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Cytarabine (BAML-16-001-S25/HO181)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Entospletinib (BAML-16-001-S6)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Decitabine (BAML-16-001-S8 Group 1)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

AZD5153 (BAML-16-001-S10)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Gilteritinib (BAML-16-001-S8 Group 2)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

BI 836858 (BAML-16-001-S2)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

AG-221 (BAML-16-001-S3)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Daunorubicin (BAML-16-001-S6)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Decitabine (BAML-16-001-S14)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

ZE46-0134 (BAML-16-001-S21 Group 2)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Cytarabine (BAML-16-001-S1)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Entospletinib (BAML-16-001-S5)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

Cytarabine (BAML-16-001-S6)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

SNDX-5613 (BAML-16-001-S17)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

ficlatuzumab (BAML-16-001-S24)

Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

mFOLFOX6

Phase 2

Colorectal Cancer

AV-299 + gefitinib

Phase 2

Carcinoma, Non-Small Cell-Lung

Frequently asked questions

What is in Aveo Pharmaceuticals, Inc.'s drug pipeline?β†’

CatalystAlert tracks 35 drug candidates in Aveo Pharmaceuticals, Inc.'s (AVEO) pipeline across Phase 3, Phase 2. Its lead program is Ficlatuzumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Aveo Pharmaceuticals, Inc.'s next FDA catalyst?β†’

Aveo Pharmaceuticals, Inc.'s (AVEO) next tracked catalyst is a Phase 3 readout expected August 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track AVEO biotech catalysts?β†’

Add AVEO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aveo Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply